

Learner Notification

MED Learning Group

Evidence-Based Strategies for Managing Fabry Disease: Considerations for Novel Therapies to Improve Outcomes

September 15, 2023 – September 15, 2024

Online

Acknowledgement of Financial Commercial Support

Amicus Therapeutics, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Identify the characteristic symptoms and signs of Fabry disease (FD) in patients to facilitate timely diagnosis and management.
2. Evaluate the clinical evidence supporting approved and investigational therapies for FD, including real-world data, to inform treatment decisions.
3. Develop effective communication skills to educate patients and caregivers about FD and its management, tailored to the patient's needs and preferences.
4. Analyze the risk factors and clinical features of cardiac and renal complications in patients with FD and select appropriate tools to assess disease progression and treatment response.
5. Assess the impact of early intervention on the efficacy of FD treatment, disease progression, and patients' quality of life.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Lisa	Crenshaw	NA
Daniel	DaSilva	NA
Matthew	Frese	NA
Christina	Gallo	NA
Debra	Gordon	NA
Morgan	Kravrik	NA
Dawn	Laney	Sanofi Genzyme: Honoraria, Research Funding as Investigator, Researcher, Speaker, Board Member, Sanofi Genzyme: Research Funding, Honoraria as Investigator, Amicus and Shire, now part of Takeda: Research Funding and Honoraria as Investigator, Speaker, Coordinator, ThinkGenetic, Inc.: Stock Options
Jacquelyn	Sandfort	NA

Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com